| Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, HD Tjørnelund, A Binderup, ... Science Advances 8 (51), eadd7197, 2022 | 114 | 2022 |
| In vitro efficacy of artemisinin-based treatments against SARS-CoV-2 Y Zhou, K Gilmore, S Ramirez, E Settels, KA Gammeltoft, LV Pham, ... Scientific Reports 11 (1), 14571, 2021 | 90 | 2021 |
| Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro KA Gammeltoft, Y Zhou, CR Duarte Hernandez, A Galli, A Offersgaard, ... Antimicrobial Agents and Chemotherapy 65 (9), 10.1128/aac. 02680-20, 2021 | 39 | 2021 |
| Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro Y Zhou, KA Gammeltoft, A Galli, A Offersgaard, U Fahnøe, S Ramirez, ... Viruses 13 (10), 2082, 2021 | 19 | 2021 |
| Nirmatrelvirresistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci Adv 8: eadd7197 Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, HD Tjørnelund, A Binderup, ... Inhibitor A (patient is resistant), 2022 | 6 | 2022 |
| Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in vitro. bioRxiv Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham, U Fahnøe, A Binderup, ... Preprint] 10 (2022.06), 06.494921, 2022 | 5 | 2022 |
| Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir KA Gammeltoft, Y Zhou, LA Ryberg, LV Pham, A Binderup, ... Viruses 15 (9), 1970, 2023 | 1 | 2023 |
| An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals A Offersgaard, CRD Hernandez, S Feng, P Marichal-Gallardo, ... Iscience 26 (2), 2023 | 1 | 2023 |
